Immune Globulin Intravenous, Human-slra (Asceniv)
Immune Globulin Intravenous, Human-slra is an FDA-licensed reference biologic from ADMA Biologics, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2019
Reference approved
Reference product
Asceniv Immune Globulin Intravenous, Human-slra
ADMA Biologics, Inc.
- Approved
- Apr 01, 2019
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Immune Globulin Intravenous, Human-slra, in chronological order.
Reference approval
Approval date of the reference Immune Globulin Intravenous, Human-slra product.
7 yr 3 mo ago
Frequently asked questions
Are there biosimilars approved for Immune Globulin Intravenous, Human-slra (Asceniv)?
No 351(k) biosimilars or interchangeable biosimilars referencing Immune Globulin Intravenous, Human-slra are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.